ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion

Navepegritide (Yuviwel)

 Treatment of achondroplasia in children

Orphan
CHMP opinion 15 Oct 2026 · Ascendis Pharma Growth Disorders A/S
US · FDA approval, new medicine

Navepegritide (Yuviwel)

To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses

Approved 27 Feb 2026

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.